Moving from in silico analyses to our experimental in vitro and in vivo data, we provided evidence that EphA2 is highly expressed in selected primary tumor samples of bone sarcomas if compared to their normal counterparts; this was demonstrated in their respective PDX models generated in our laboratory in NSG mice. This evidence concerns the gene EPHA2 and bone sarcoma.